| NCT ID | NCT07402616 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Cutaneous Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-02-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective study including patients ( ≥ 18 years) referred for surgical treatment of primary cutaneous squamous cell carcinoma at the Department of Plastic Surgery, Rigshospitalet. After written and informed consent, patients will undergo standard surgical excision, followed by ex vivo 3D ultrasonography of the specimen using a 3Sonic device connected to a high-frequency ultrasound machine. This will create 3D ultrasound tomographic scans which will be interpreted by one investigator blinded to histopathology. The investigated outcomes will primarily be the deep margin distance. This will be compared to histopathology, where a pathologist - blinded to the ultrasonography results - will slice the entire specimen parallel to the ultrasound images. A third investigator will then match the histopathology images to the ultrasound images for correlation of the measured deep margins.
Eligibility Criteria
Inclusion Criteria: * Adults with primary cutaneous squamous cell carcinoma. Exclusion Criteria: * Carcinomas located on the eyelids, vulva, penis, or perianal. * Tumors with an anticipated excision larger than 60mm.
Contact & Investigator
Tobias Todsen, MD, PhD
STUDY CHAIR
Rigshospitalet, Denmark
Frequently Asked Questions
Who can join the NCT07402616 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cutaneous Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07402616 currently recruiting?
Yes, NCT07402616 is actively recruiting participants. Contact the research team at linnea.langhans@regionh.dk for enrollment information.
Where is the NCT07402616 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07402616 clinical trial?
NCT07402616 is sponsored by Rigshospitalet, Denmark. The principal investigator is Tobias Todsen, MD, PhD at Rigshospitalet, Denmark. The trial plans to enroll 30 participants.